In our current studies, the anti-PDL1 serves as a tumor targeting agent only because we have only tested the anti-PD-L1 NIC for tumor response in athymic nude mice; hence, we cannot access immune system fluctuations caused by treatment. Here, CD274 is linked to neoplasm.